Royalty Pharma (NASDAQ:RPRX) Hits New 1-Year Low – What’s Next?

Royalty Pharma plc (NASDAQ:RPRX) reached a new 52-week low on Friday . The company traded as low as $25.12 and last traded at $25.64, with a volume of 394313 shares. The stock had previously closed at $25.58.

Analyst Upgrades and Downgrades

A number of research firms have commented on RPRX. Citigroup decreased their target price on shares of Royalty Pharma from $60.00 to $40.00 and set a “buy” rating on the stock in a research report on Friday, October 25th. The Goldman Sachs Group upped their price objective on shares of Royalty Pharma from $50.00 to $51.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. Finally, StockNews.com upgraded shares of Royalty Pharma from a “hold” rating to a “buy” rating in a report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $41.67.

Royalty Pharma Trading Up 1.8 %

The company has a debt-to-equity ratio of 0.64, a current ratio of 1.54 and a quick ratio of 1.54. The firm has a market cap of $15.32 billion, a PE ratio of 13.25, a price-to-earnings-growth ratio of 3.78 and a beta of 0.47. The company’s 50 day moving average price is $27.53 and its 200 day moving average price is $27.48.

Royalty Pharma Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be given a $0.21 dividend. The ex-dividend date is Friday, November 15th. This represents a $0.84 annualized dividend and a yield of 3.25%. Royalty Pharma’s dividend payout ratio is presently 43.52%.

Institutional Trading of Royalty Pharma

A number of large investors have recently modified their holdings of RPRX. Versant Capital Management Inc grew its stake in Royalty Pharma by 5,215.0% during the 2nd quarter. Versant Capital Management Inc now owns 1,063 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 1,043 shares in the last quarter. Gladius Capital Management LP acquired a new position in shares of Royalty Pharma during the second quarter worth about $32,000. Blue Trust Inc. increased its stake in shares of Royalty Pharma by 362.7% during the third quarter. Blue Trust Inc. now owns 1,203 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 943 shares during the period. EverSource Wealth Advisors LLC raised its holdings in Royalty Pharma by 32.1% in the second quarter. EverSource Wealth Advisors LLC now owns 2,698 shares of the biopharmaceutical company’s stock valued at $76,000 after acquiring an additional 655 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its stake in Royalty Pharma by 4,335.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 2,750 shares of the biopharmaceutical company’s stock worth $84,000 after acquiring an additional 2,688 shares during the last quarter. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.